- Long-term investment holding acquires majority stake in market leader of innovative planning software for endoprosthetic surgeries in the German-speaking region
- Injection of growth capital for investments in continued product innovation, internationalization and add-on acquisitions
- mediCAD as nucleus for new growth platform, focused on software solutions for the healthcare industry
- Previous owner Joern Seel remains shareholder and CEO of the Group
Since its acquisition by Joern Seel in 2010, mediCAD has become market leader for preoperative endoprosthetic planning software in the German-speaking region with approx. 5,000 installed software modules. The Group has also established itself as innovation leader in more than 30 countries. As a dedicated joint and bone specialist, mediCAD has consistently enhanced its software suite. Today, it comprises the world's most comprehensive range of 2D and 3D planning modules, amongst others in the application areas of hip, spine, knee, ankle, shoulder, hand, elbow and trauma. More than 600,000 implant and accessory templates from all leading manufacturers are integrated into the software through a proprietary database which can be directly accessed by physicians as part of their planning routine. As innovation leader, mediCAD systematically invests in flagship R&D projects, at present particularly in the areas of mixed reality and artificial intelligence.
As a long-term investment holding, HQIB fully supports the future growth strategy of mediCAD. The main focus lies on the continued development of the software portfolio and further internationalization, especially in North America and Asia. Furthermore, the Group shall be expanded through acquisitions of complementary software solutions and technologies.
Joern Seel, CEO mediCAD: "HQIB is the renowned, technology savvy and long-term oriented partner we have been searching for. We are proud of this partnership. Together, we are well positioned to develop mediCAD into a global market leader while further strengthening our innovation leadership. The injected growth capital will be invested in the consistent build-up of resources in R&D and sales. As a financially sound partner, HQIB will provide further funds for strategic acquisitions. Lastly, the global Harald Quandt network will support our growth ambitions."
"With mediCAD, we have found the ideal nucleus for a new growth platform in the field of software solutions for the healthcare industry. We are thankful for the trust placed in us. HQIB supports Joern Seel and his team in continuing to provide orthopedists and surgeons with first- class, innovative software for endoprosthetic procedures, thereby significantly increasing treatment results, patient safety and the efficiency of workflows in hospitals and clinics," explains Gregor Harald May, Managing Partner at HQIB.
"With its high innovation and broad sales network, mediCAD is well positioned for future growth. In addition to the German-speaking markets and Europe, we expect a continued growth momentum particularly in North America and Asia. Regulatory requirements are increasing, and digitization is becoming more and more popular. That is why we see great potential for innovative software solutions in the healthcare industry," adds Philipp Steinfeld, Director at HQIB.
About Harald Quandt Industriebeteiligungen
Harald Quandt Industriebeteiligungen GmbH is an investment company of the Harald Quandt family and a small number of selected (industrial) families and partners. HQIB invests in small and medium-sized companies in German-speaking countries that are active in established, future-oriented and technically sophisticated sectors with attractive growth potential. As an industrial holding, HQIB pursues a long-term and sustainable investment approach and is not subject to maturity restrictions or limited holding periods. For more information, please visit www.hq-ib.com.
